Dr Reddy's gets CDSCO panel nod to study Darbepoetin alfa
New Delhi: The drug major Dr Reddy's Laboratories has got a green signal from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the pharmacokinetic/ pharmacodynamic (PK/PD) clinical trial of the Darbepoetin alfa which is used to treat anaemia.
However, this approval is subject to condition that the range of the haemoglobin during a screening of the subjects should be 12-14 gm/dl and the complete iron profile should be monitored including serum iron, total iron-binding capacity (TIBC), transferrin saturation and serum creatinine.
This came after the firm presented the proposal for the conduct of a PK/PD clinical trial titled “A single dose, double-blind, two-period crossover, balanced sequences, comparative pharmacokinetic study with separate comparisons of three pairs of products of DRL- Darbepoetin (DRL_DA), US licensed reference Product (Aranesp), and EU approved reference Medicinal Product (Aranesp), administered by the subcutaneous route to male healthy volunteers vide Protocol number: DA-01-006; version 1.0 dated 04.08.2022”.
Darbepoetin alfa is a recombinant form of human erythropoietin used to increase the differentiation of progenitor cells to red blood cells in the treatment of anaemia.
At the recent SEC meeting for Cardiovascular and Renal held on 21st February 2023, the expert panel reviewed the proposal presented by drug major Dr Reddy's to conduct the PK/PD clinical trial of Darbepoetin alfa.
After detailed deliberation, the committee recommended the grant of permission to conduct the clinical trial subject to the following conditions:
Accordingly, the expert panel directed that the firm should submit the revised protocol to CDSCO for approval.
Also Read:Submit justification: CDSCO panel tells Hetero for FDC Lacosamide, Brivaracet
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.